TL;DR
This Phase II study investigated a novel oral combination of niraparib (a PARP inhibitor) and anlotinib (an antiangiogenic tyrosine kinase inhibitor) for platinum-resistant ovarian cancer (PROC). The combination demonstrated promising anti-tumor activity, achieving a 50% objective response rate and a median progression-free survival of 9.2 months, with a manageable safety profile. This suggests a potential new, convenient treatment option for patients with PROC, a group with limited therapeutic choices.
What Problem Does This Paper Address?
Epithelial ovarian cancer, despite initial responses to platinum-based chemotherapy, frequently recurs and becomes resistant to platinum. Platinum-resistant recurrent ovarian cancer (PROC) represents a significant clinical challenge with a poor prognosis and limited effective treatment options. While single-agent antiangiogenics and PARP inhibitors have shown some activity in this setting, their efficacy is often modest, and PARP inhibitors are particularly effective in patients with BRCA mutations or homologous recombination deficiency (HRD). The paper addresses the need for more effective and broadly applicable treatments for PROC by exploring the combination of niraparib and anlotinib, two drug classes with distinct mechanisms that may offer synergistic anti-tumor effects.
Methods
The ANNIE study was a multicenter, single-arm, Phase II clinical trial. Eligible patients with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer that recurred within six months of their last platinum-based chemotherapy were enrolled. Patients with prior PARP inhibitor exposure were excluded. The treatment regimen consisted of oral niraparib (200 mg or 300 mg daily, weight-directed) and oral anlotinib (10 mg daily on days 1-14 of a 21-day cycle) until disease progression or intolerable toxicity. The primary endpoint was the objective response rate (ORR), with secondary endpoints including progression-free survival (PFS) and overall survival (OS). Safety was assessed by monitoring treatment-emergent adverse events (TEAEs).
Datasets
Not discussed in the paper. The study involved patient enrollment and treatment, with data collected on their clinical characteristics, treatment response, and safety outcomes.
Key Insights and Ideas
- Synergistic Potential: The combination of a PARP inhibitor (niraparib) and an antiangiogenic TKI (anlotinib) is hypothesized to work synergistically. PARP inhibition can lead to DNA damage, while antiangiogenics can induce HRD and potentially enhance the effects of PARP inhibitors. Conversely, PARP inhibition might also have antiangiogenic effects.
- Broad Applicability: The observed 50% ORR in the ITT population, with only 13% of patients having a germline BRCA mutation, is particularly encouraging. This suggests that the niraparib-anlotinib combination may overcome the biomarker limitations often associated with PARP inhibitor monotherapy, offering benefits to a wider patient population with PROC.
- Manageable Safety Profile: Despite combining two active agents, the combination was generally well-tolerated, with no new safety signals compared to individual agents. The most common grade ≥3 TEAEs were manageable, and importantly, there were no treatment-related deaths.
- Convenient Oral Regimen: The oral administration of both niraparib and anlotinib offers a convenient treatment option, potentially improving patient quality of life compared to intravenous therapies.
Key Results
- Objective Response Rate (ORR): The ITT population achieved an ORR of 50.0% (95% CI 33.8–66.2), including one complete response and 19 partial responses. For the efficacy-evaluable population (36 patients), the ORR was 55.6%.
- Progression-Free Survival (PFS): The median PFS was 9.2 months (95% CI 7.4–11.9).
- Overall Survival (OS): The median OS was 15.3 months (95% CI 13.9–not evaluable).
- Safety: Drug-related, grade ≥3 TEAEs were reported in 26 (68%) patients. The most common grade ≥3 TEAEs included neutrophil count decrease (18%), hand-foot syndrome (15%), and hypertension (13%). No treatment-related deaths occurred.
- Tumor Shrinkage: 86% of efficacy-evaluable patients experienced a decrease in the sum of their target lesion diameters at best overall response.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size and Single-Arm Design: The study was a Phase II trial with a small sample size (40 patients) and a single-arm design. The observed efficacy and safety will need to be validated in larger, randomized controlled trials.
- HRD Status Determination: Difficulties in obtaining valid specimens from heavily pre-treated patients precluded a definitive determination of the relationship between HRD status and efficacy.
- Exclusion of Prior PARP Inhibitor Patients: The study excluded patients with prior PARP inhibitor exposure, a group that is increasingly common in PROC. An expansion study (ANNIE Plus) is planned to address this.
- COVID-19 Pandemic Impact: The pandemic necessitated modifications to on-site follow-ups, relying more on telephone contact and postal delivery of medications.
Future work will involve validating these findings in larger randomized trials, including the planned ANNIE Plus study. Further investigation into the role of molecular biomarkers like PPM1D and SPEN mutations in predicting response and resistance is also warranted. The authors aim to further optimize the prevention and management of TEAEs to improve patient outcomes and quality of life.
Summary updated